CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
HBV | Webcasts Back
  Release Date 02/22/2012
Expiration Date 02/22/2013
This program has expired. CME credit is no longer available.
  Robert Gish, MD  
  Chief of Hepatology
Co-Director of the Center for
Hepatobiliary Disease and
Abdominal Transplantation (CHAT)
University of California, San Diego
San Diego, CA
  View Webcast  
  Jointly sponsored by Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.  
  This activity supported by:  
  Bristol-Myers Squibb.  
Target Audience
This activity has been designed to meet the educational needs of healthcare practitioners involved in the care of patients with HBV.
Statement of Need/Program Overview
The goal of this program is to provide important clinical data on the management of HBV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
Recognize the link between long term HBV suppression and regression of fibrosis
Understand the sequencing of therapy to prevent development of resistance
Review safety profile of long term treatment of HBV with various agents
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Purdue University College of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosure Statement
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Dr Gish has received grants/research support from Bayer-Onyx, Bristol-Myers Squibb, Genentech/Hoffman-LaRoche, Gilead Sciences, Pharmasset, and ZymoGenetics. He has served as a consultant for Abbott, Anadys Pharmaceuticals, Inc., Bayer, Bristol-Myers Squibb, Durect, Hepahope, Hoffman-LaRoche Ltd., Genentech, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Human Genome Sciences, Merck, Metabasis Therapeutics, OSI/Astellas, Pharmasset, Schering-Plough, Three Rivers, VitalTherapies, and ZymoGenetics. Dr. Gish has served on the speakers bureau for Bayer, Bristol-Myers Squibb, Hoffman-LaRoche Ltd., Gilead Sciences, GlaxoSmithKline, Onyx, Merck, Schering-Plough, Roche, Three Rivers, Salix and SciClone Pharmaceuticals.
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.